Results 71 to 80 of about 222,862 (245)
ANTIGENICITY STUDY OF PACLITAXEL
The Journal of Toxicological Sciences, 1994 The antigenic property of paclitaxel was examined using its protein mixtures (paclitaxel + OVA, paclitaxel + GSA, paclitaxel + RSA) in guinea pigs and mice in comparison with ovalbumin (OVA) and the protein conjugate of 4-aminoantipriyne (AAP). The following results were obtained: 1.
Katsumi Ishikawa +4 more
openaire +4 more sources
Advanced Science, EarlyView.In this study, a targeting PFKFB4 biomimetic codelivery system is developed to improve paclitaxel efficacy by inducing ferroptosis in SCLC. This system enhances immune cell infiltration and cytokine secretion, activating anti‐tumor immunity. Combined with anti‐PD‐L1, it boosts immune responses, offering a novel therapeutic strategy for overcoming ...
Xiang Liu +9 more
wiley +1 more source
Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial [PDF]
, 2016 Vaccination with priming and expansion of tumour reacting T cells is an important therapeutic option to be used in combination with novel checkpoint inhibitors to increase the specificity of the T cell infiltrate and the efficacy of the treatment. In
Antonilli M +13 more
core +1 more source
The dark side of paclitaxel [PDF]
Oncology Reviews, 2010 The bark extract of Pacific Yew (Taxus brevifolia) was first reported to have anti-tumor activity in 1963. The active constituent responsible for this activity was later identified in 1971 as paclitaxel [1]. Paclitaxel is a cytotoxic drug used in the treatment of variety of tumors including ovarian, breast, and non-small-cell lung cancers...
openaire +2 more sources
Advanced Science, EarlyView.PRMT1 drives carboplatin resistance and tumor progression in head and neck squamous cell carcinoma (HNSCC) through a novel, methyltransferase‐independent mechanism. It recruits the SWI/SNF complex to activate IGF2BP2, promoting tumor growth and carboplatin resistance. PBX2 upregulates PRMT1, reinforcing this pathway. This study uncovers a non‐catalytic
Shixian Liu +22 more
wiley +1 more source
Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis, and chemotherapeutic resistance via accumulation of MCL1 [PDF]
, 2018 学位記番号 ...
Ishii, Norihiro +2 more
core
Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer. [PDF]
, 2017 Breast cancer remains the leading cause of cancer death in women owing to metastasis and the development of resistance to established therapies. Macrophages are the most abundant immune cells in the breast tumor microenvironment and can both inhibit and ...
A Fantozzi +66 more
core +2 more sources
Advanced Science, EarlyView.This study provides new perspectives into the interactions between mechanical forces and cellular dynamics within the tumor microenvironment, particularly elucidating how minority Paclitaxel‐resistant cancer cells (MRCs) promote tumor progression and treatment resistance through mechanical forces and also providing effective treatment strategies for ...
Xueyan Feng +12 more
wiley +1 more source
Advanced Science, EarlyView.A CTGF‐LYTAC nanoplatform is developed to selectively degrade connective tissue growth factor (CTGF) in triple‐negative breast cancer (TNBC), inhibiting TGF‐β signaling and cell interactions in the tumor microenvironment (TME). This strategy effectively suppresses tumor growth and metastasis, outperforming antibody‐based therapy.
Jia‐Yi Lin +11 more
wiley +1 more source
Advanced Science, EarlyView.The P6CIT lipopolymer demonstrates superior transfection efficacy in the spinal cord and DRG, as well as enhanced penetration of the pia mater compared to the MC3 ionizable lipid. Intrathecal delivery of P6CIT LPNPs enables effective transfection in the gliocytes in the spinal cord and DRG.
Xinrou Lin +10 more
wiley +1 more source